274 related articles for article (PubMed ID: 27048336)
1. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
[TBL] [Abstract][Full Text] [Related]
2. Recent discovery and development of AXL inhibitors as antitumor agents.
Liu Z; Chen L; Zhang J; Yang J; Xiao X; Shan L; Mao W
Eur J Med Chem; 2024 Jun; 272():116475. PubMed ID: 38714043
[TBL] [Abstract][Full Text] [Related]
3. Research Progress of Axl Inhibitors.
Sun ZG; Liu JH; Zhang JM; Qian Y
Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
5. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu C; Wei Y; Wei X
Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
[TBL] [Abstract][Full Text] [Related]
6. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
7. Axl inhibitors as novel cancer therapeutic agents.
Shen Y; Chen X; He J; Liao D; Zu X
Life Sci; 2018 Apr; 198():99-111. PubMed ID: 29496493
[TBL] [Abstract][Full Text] [Related]
8. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
Linger RM; Keating AK; Earp HS; Graham DK
Expert Opin Ther Targets; 2010 Oct; 14(10):1073-90. PubMed ID: 20809868
[TBL] [Abstract][Full Text] [Related]
9. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
[TBL] [Abstract][Full Text] [Related]
10. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors.
Choi MJ; Roh EJ; Hur W; Lee SH; Sim T; Oh CH; Lee SH; Kim JS; Yoo KH
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3761-3765. PubMed ID: 30340900
[TBL] [Abstract][Full Text] [Related]
13. AXL kinase as a novel target for cancer therapy.
Wu X; Liu X; Koul S; Lee CY; Zhang Z; Halmos B
Oncotarget; 2014 Oct; 5(20):9546-63. PubMed ID: 25337673
[TBL] [Abstract][Full Text] [Related]
14. Targeting Axl and Mer kinases in cancer.
Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S
Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
[TBL] [Abstract][Full Text] [Related]
16. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells.
Kim NY; Lee HY; Lee C
Int J Oncol; 2015 Jul; 47(1):353-60. PubMed ID: 25975389
[TBL] [Abstract][Full Text] [Related]
17. Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy.
Goff D; Zhang J; Heckrodt T; Yu J; Ding P; Singh R; Holland S; Li W; Irving M
Bioorg Med Chem Lett; 2017 Aug; 27(16):3766-3771. PubMed ID: 28711351
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
Tian M; Chen XS; Li LY; Wu HZ; Zeng D; Wang XL; Zhang Y; Xiao SS; Cheng Y
Acta Pharmacol Sin; 2021 Jul; 42(7):1180-1189. PubMed ID: 33149145
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.
Keating AK; Kim GK; Jones AE; Donson AM; Ware K; Mulcahy JM; Salzberg DB; Foreman NK; Liang X; Thorburn A; Graham DK
Mol Cancer Ther; 2010 May; 9(5):1298-307. PubMed ID: 20423999
[TBL] [Abstract][Full Text] [Related]
20. 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.
Tan L; Zhang Z; Gao D; Luo J; Tu ZC; Li Z; Peng L; Ren X; Ding K
J Med Chem; 2016 Jul; 59(14):6807-25. PubMed ID: 27379978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
